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ABSTRACT 
Background/aims  
Retinal screening programmes in England and Scotland have similar 
photographic grading schemes for background (non-proliferative) and 
proliferative diabetic retinopathy, but diverge over maculopathy. We looked for 
the most cost-effective method of identifying diabetic macular oedema from 
retinal photographs; including the role of automated grading and optical 
coherence tomography, a technology that directly visualises oedema.  
Methods  
Patients from seven UK centres were recruited. The following features in at least 
one eye were required for enrolment: microaneurysms/dot haemorrhages or blot 
haemorrhages within one disc diameter, exudates within one or two disc 
diameters of the centre of the macula. Subjects had optical coherence 
tomography and digital photography. Manual and automated grading schemes 
were evaluated. Costs and QALYs were modelled using microsimulation 
techniques.  
Results  
3540 patients were recruited, 3170 were analysed. For diabetic macular 
oedema, England’s scheme had a sensitivity of 72.6% and specificity of 66.8%; 
Scotland’s a sensitivity of 59.5% and specificity of 79.0%. When applying a 
ceiling ratio of £30,000 per QALY gained, Scotland’s scheme was preferred. 
Assuming automated grading could be implemented without increasing grading 
costs, automation produced a greater number of QALYS for a lower cost than 
England’s scheme, but was not cost effective, at the study’s operating point, 
compared to Scotland’s. The addition of optical coherence tomography, to each 
scheme, resulted in cost savings without reducing health benefits.  
Conclusion  
Retinal screening programmes in the United Kingdom should reconsider the 
screening pathway to make best use of existing and new technologies.  
 
INTRODUCTION 
Diabetic retinal screening programmes in the United Kingdom differ over how 
surrogate photographic markers are used to screen patients for diabetic macular 
oedema. England utilises exudates within two disc diameters of the centre of the 
macula and, if visual acuity is reduced, blot haemorrhages and 
microaneurysms/dot haemorrhages within one disc diameter. Scotland only 
utilises exudates and blot haemorrhages within one disc diameter, regardless of 
the visual acuity. 
We investigated the accuracy and cost-effectiveness of these schemes using 
optical coherence tomography (OCT), a technology that directly visualises 
oedema, as the reference standard. Additionally we investigated the accuracy 
and cost-effectiveness of automated grading and the role of OCT in screening for 
diabetic macular oedema.[1-3] 
MATERIALS AND METHODS 
This was a multi-centre, prospective, observational cohort study. Participants 
with diabetes were recruited from retinopathy screening and ophthalmology in 
Aberdeen, Birmingham, Dundee, Dunfermline, Edinburgh, Liverpool and Oxford. 
Patients aged 18 or older who gave informed consent were included. The 
following photographic features in at least one eye were required for 
recruitment: microaneurysms/dot haemorrhages or blot haemorrhages within 
one disc diameter, exudates within one or two disc diameters of the centre of 
the macula. Exclusions were: pregnancy; contra-indications to dilatation; 
intraocular surgery within one year; macular or pan-retinal laser treatment; or 
intraocular injection. The reference standard was an adequate OCT image of 
both eyes. Patients were omitted from analysis if they had an inadequate OCT 
image in either eye. Patients with an adequate retinal photograph in one eye 
were included.  
To avoid inter-centre variation, OCT operators submitted a portfolio of images 
for accreditation.  
A 45º macula-centred colour digital retinal photograph (3-8 megapixels, with or 
without JPEG compression) was obtained from each eye. OCT images were 
obtained from each eye producing a nine subfield “Early Treatment of Diabetic 
Retinopathy Study” (ETDRS) map showing average regional thickness, and a 
horizontal cross-section through the centre of the macula or the region of 
greatest thickness.[4] The outer four regions were disregarded. Best logMAR 
visual acuity was recorded unaided, with pinhole or with glasses. There was a 
maximum of 4 weeks between photograph and OCT scan.  
All images were graded and annotated by a quality assured grader (94·3% 
sensitivity, 95·7% specificity, for referable retinopathy/maculopathy, 2012[5]) 
prior to reviewing the OCT data Borderline images were referred to a senior 
ophthalmologist.  
Diabetic macular oedema was deemed present if: 
 Central ETDRS region thickness >250 µm or any of inner five regions 
>300 µm; 
 AND visible intra-retinal cyst or area of sub-retinal fluid on OCT cross-
section; 
 AND no other visible cause for macular oedema e.g. vein occlusion.  
Thickness thresholds were adjusted to account for all scanners used in the 
study.[3]  
Grading Schemes 
England’s, Scotland’s and a hybrid scheme, utilising features from both, were 
assessed (Table 1).  
A fully automated grading scheme was developed utilising existing 
software.[6,7] Automated inputs included: image feature intensity; image 
clarity; counts of microaneurysms/dot haemorrhages within one disc diameter 
and two disc diameters; likelihoods of haemorrhages within one disc diameter 
and anywhere in the image; likelihoods of exudates within one disc diameter, 
two disc diameters and anywhere in the image; and visual acuity. 
TABLE 1 Referral criteria for manual grading strategies.  
Criteria for 
referral to 
Ophthalmology 
Micro-
aneurysm/dot 
haema 
within 1 DD 
Blot haem. 
within 1 DD 
Exudate  
within 1 DD 
Exudate 
within 1-2 DD 
(if not in 1 
DD) 
England Only if   
logMAR VA 
0·3 or worse 
Only if  
logMAR VA 
0·3 or worse 
Yes Yes 
Scotland No Yes Yes No 
Hybrid Only if  
logMAR VA 
0·3 or worse 
Yes Yes No 
a haem = haemorrhage/s  
Patients with inadequate quality photographs, but no referable disease, were 
sent for slit-lamp examination, reflecting clinical practice. For automated 
grading, it was assumed that patients assigned the outcome of inadequate 
quality photographs would be referred for manual grading (hybrid grading 
scheme), and then to slit-lamp, if manual grading concurred.  
To identify sampling bias, patients were classified into a hierarchy of five 
mutually exclusive categories of features present in either eye: 
1. Exudates within one disc diameter. 
2. Blot haemorrhages, but no exudates, within one disc diameter.  
3. Microaneurysms/dot haemorrhages, but no exudates or blots, within 
one disc diameter. 
4. Exudates within one -two disc diameters with no relevant diabetic 
retinopathy features within one disc diameter.  
5. None of the above. 
Weighting was undertaken to correct for sampling bias, based on observed 
proportions of the above categories in a consecutive cohort of 6,900 patients 
attending retinal screening in Grampian.[8,9] Each weight[10-12] was calculated 
as the ratio of the observed proportion in the cohort study[9] to that in the 
present study.  
For both weighted and unweighted data, the sensitivity and specificity of using 
each investigated scheme were estimated at the patient level.[13] For these 
calculations, referral of the patient corresponded to a scheme applied to both 
eyes separately indicating referral in either eye (or both). 
Cost Effectiveness Analysis 
A Markov microsimulation model was developed to assess the cost-effectiveness 
of the alternative grading schemes for triggering referral in the context of annual 
screening, with and without OCT prior to referral. A time horizon of 20 years was 
adopted. Based on epidemiological and clinical effectiveness data, the model 
simulated the progression of macular oedema and visual loss in each eye of 
referred and un-referred patients. The model assumed that patients with 
macular oedema would receive laser treatment, whilst those not referred would 
be screened one year later.[14,15] An alternative scenario was modelled 
whereby only those with macular oedema and visual acuity ≥0·3 logMar received 
laser. Health care costs associated with photographic screening (£46·69 per 
patient), the addition of OCT to the screening pathway (£31·96 per patient), 
initial referral (£143·35), treatment (£160 per treatment per eye), on-going 
monitoring (£117 per visit)) were estimated from a resource use questionnaire 
sent to participating centres and other published sources.[16,17]  Health and 
social care costs of severe vision loss (£6,295 per year) were taken from a 
previous study.[18] See web appendix.  
The analysis simulated the passage of 100,000 “patients", with characteristics 
matching those of patients in the clinical dataset, through the model individually. 
As above, the proportions of patients in the different feature categories were 
weighted. The impact of using alternative grading schemes within annual 
screening was assessed by applying the weighted sensitivities and specificities 
within the model. Modelling was also used to assess the cost per case of macular 
oedema detected from one round of screening for this cohort (see appendix). 
The mean costs, years free of moderate visual loss (in either eye) and quality 
adjusted life years accruing to patients, under the alternative grading schemes, 
were compared to estimate incremental cost-effectiveness ratios (ICERs). The 
schemes were compared both with and without the use of OCT prior to referral. 
We also assessed a scheme (Scheme A) whereby anyone with markers of 
diabetic maculopathy would be examined with OCT. A ceiling willingness to pay 
ratio of £30,000 per QALY gained was applied to identify the optimal scheme on 
grounds of cost-effectiveness.[19]  
To characterise the uncertainty surrounding the cost-effectiveness of 
alternatives, deterministic and probabilistic sensitivity analyses were 
undertaken. The probabilistic analysis sampled from distributions assigned to 
each model parameter, and simulated the passage of 10,000 patients through 
the model 1000 times. This produced 1000 estimates of the mean cost and 
effects for each scheme. Cost-effectiveness acceptability curves were produced 
by calculating the proportion of these iterations favouring each of the schemes 
(on grounds of cost-effectiveness) at different ceiling ratios of willingness to pay 
per QALY.[20] The methods used to derive probabilities for visual loss and the 
development of macular oedema precluded determination of the statistical 
impression surrounding these estimates. The impact of variation in these 
parameters was addressed through deterministic sensitivity analysis.  
RESULTS 
3540 patients were recruited between 31/07/2008 and 22/02/2011 (Figure 1). 
370 were excluded from analysis: in 329 the OCT failed in at least one eye; in a 
further 41 retinal photographs from both eyes were of inadequate quality; and 
there was 1 lost image (Figure 2).  
3170 patients were analysed (Table 2) of which 243 (7·7%) had diabetic 
macular oedema. Prevalence of diabetic macular oedema differed between 
centres (range 3·7% to 12·2%) and scanners (range 4·5% to 11·8%). Diabetic 
macular oedema was statistically commoner in older people, Caucasians, those 
with type 2 diabetes or poor visual acuity. 
When mutually exclusive categories of lesions were considered, diabetic macular 
oedema was present in 14·1% of those with exudates within one disc diameter; 
12·1% of those with blot haemorrhages (but no exudates within one disc 
diameter); and 3·2% of those with microaneurysms/dot haemorrhages (and no 
exudates or blot haemorrhages within one disc diameter) (Table 2). 
Table 3 shows the analysis weights used to correct for sampling bias. Exudates 
within one disc diameter and blot haemorrhages were down weighted. Exudates 
between one and two disc diameters and microaneurysms/dot haemorrhages 
were up weighted. 
Table 4 shows the sensitivities and specificities for predicting the presence of 
diabetic macular oedema from certain lesion combinations for unweighted and 
weighted data. The presence of exudates within one disc diameter had the 
greatest influence on the prediction of macular oedema. The addition of 
exudates between one -two disc diameters did not identify any further cases 
(Table 4). 
TABLE 2 Demographics by optical coherence tomography macular oedema status 
 Total 
n 
% Oedema 
present 
(At 
least 
one 
eye) n 
% Oedema 
absent 
(Both 
eyes) n 
% p-value 
(oedema 
present 
vs. 
absent) 
Number of cases 3170  243  2927   
Age †median 
(interquartile 
range) 
60† (49, 
69) 
67† (58, 
75) 
59† (48, 
69) 
<0·001 
Sex (male) 1925 60·7 147 60·5 1778 60·7 0·993 
Ethnicity       0·015 
Caucasian 2678 84·5 223 91·8 2455 84·5  
Asian 369 11·6 16 6·6 353 12·1  
Black 74 2·3 2 0·8 72 2·5  
Other/Unknown 49 1·5 2 0·8 47 1·6  
Diabetes:       <0·001* 
Type 1 709 22·4 28 11·5 681 23·3  
Type 2 2452 77·4 213 87·7 2239 76·5  
Unspecified 4 0·1 2 0·8 2 0·1  
Unknown 5 0·2 0 0·0 5 0·2  
        
Glitazone use (yes) 177 5·6 10 4·1 167 5·7 0·372 
Amblyopia (either 86 2·7 83 2·8 3 1·2 0·204 
 Total 
n 
% Oedema 
present 
(At 
least 
one 
eye) n 
% Oedema 
absent 
(Both 
eyes) n 
% p-value 
(oedema 
present 
vs. 
absent) 
yes) 
Visual acuity (Left 
eye)‡ 
      <0·001 
Better 
(logMAR<0·3) 
2807 88·5 163 67·1 2644 90·3  
Worse 
(logMAR≥0·3) 
348 11·0 77 31·7 271 9·3  
Missing 15 0·5 3 1·2 12 0·4  
Visual acuity‡ 
(Right eye) 
      <0·001 
Better 
(logMAR<0·3) 
2794 88·1 164 67·5 2630 89·9  
Worse 
(logMAR≥0·3) 
361 11·4 74 30·5 287 9·8  
Missing 15 0·5 5 2·1 10 0·3  
Mutually exclusive 
categories 
      <0·001 
Exudates < 1 DD 1024 32·3 144 59·3 880 30·1  
Blots (no exudates) 
< 1 DD 
423 13·3 51 21·0 372 12·7  
Microaneurysms 1371 43·2 44 18·1 1327 45·3  
 Total 
n 
% Oedema 
present 
(At 
least 
one 
eye) n 
% Oedema 
absent 
(Both 
eyes) n 
% p-value 
(oedema 
present 
vs. 
absent) 
only < 1 DD  
Exudates 1-2 DD 27 0·9 0 0·0 27 0·9  
No relevant diabetic 
retinopathy 
features <2DD 
325 10·3 4 1·6 321 11·0  
DD disc diameter radius 
*Comparison of 3 categories of diabetes (type 1, type 2 and other) as unknown 
and unspecified combined for statistical test.  
‡Visual acuity better (logMAR<0·3, Snellen 6/9·5 or better) and visual acuity 
worse (logMAR≥0·3, Snellen 6/12 or worse) 
TABLE 3 Patient category proportions used in the statistical and cost-
effectiveness analyses 
Category Proportion in 
earlier study 
Number 
in current 
study 
Weights for 
weighted 
analysis  
Exudate(s) within 1 DD 203/1099 = 
0·185 
1024 0·572 
blot haemorrhage(s) (no 
exudates) within 1 DD 
50/1099 = 
0·045 
423 0·341 
Microaneurysm(s)/dot 
haemorrhage(s) (no 
blots) within 1 DD 
829/1099 = 
0·754 
1371 1·744 
Exudate(s) between 1 & 
2 DD 
17/1099 = 
0·015 
27 1·816 
No relevant DR features 
within macula 
 325 0 
Excluded  370 0 
DD disc diameter 
TABLE 4 Sensitivity and specificity for the manually identified lesions 
 Unweighted Weighted 
 N=3170 
Macular Oedema N=243 
N=3170 
Macular Oedema N=176 
Lesion within 1 
DD 
MO  
N 
Not 
MO  
N 
Sens 
% 
Spec 
% 
PPV 
% 
NPV 
% 
MO 
N* 
Not 
MO  
N* 
Sens 
% 
Spec 
% 
PPV 
% 
NPV 
% 
MA only 44 1327 18·1 54·7 3·2 88·9 77 2314 43·8 22·7 3·2 87·3 
MA or blots (no 
exudates) 
95† 1699 39·1 42·0 5·3 89·2 94 2441 53·4 18·4 3·7 87·1 
MA or blots or 
exudates 
239 2579 98·4 11·9 8·5 98·9 176 2944 100·0 1·7 5·6 100·0 
MA or blots or 
exudates or 
exudates 1-2 
DD 
239 2606 98·4 11·0 8·4 98·8 176 2993 100·0 0·0 5·6 N/A 
*Counts in the weighted analysis are rounded to the nearest whole number 
†The numbers presented are cumulative. There are 95 with MA or blots (44 with MA only and 51 with blots or both MA and 
blots) 
England’s scheme, after weighting, had sensitivity of 72·6% and specificity of 
66·8% for detection of diabetic macular oedema; Scotland’s sensitivity of 59·5% 
and specificity of 79%. The hybrid scheme had sensitivity of 73·3% and 
specificity of 70·9% (Table 5). 
The receiver operating characteristic curve for automated grading is shown in 
Figure 3 together with the sensitivities and specificities for the three manual 
schemes. Compared to the manual schemes, for the same sensitivity, automated 
grading achieved a higher specificity. The automated system operating point 
used in the cost-effectiveness analysis had slightly higher sensitivity (75·9%) 
and specificity (73·7%) than the hybrid manual grading scheme (Table 5).  
The results of the short term analysis of the cost per case detected from one 
round of screening are presented in the web appendix.  
Table 6 shows the results of the cost-effectiveness analysis. The addition of OCT 
to each scheme resulted in cost-savings without reducing health benefits. 
Scotland’s scheme was found to be most cost-effective at the accepted ceiling 
ratio of £30,000 per QALY, with or without the addition of OCT. Even scheme A, 
where any one with markers of diabetic maculopathy is examined with OCT, 
produces cost savings over all the manual schemes without OCT. 
In the study, automated grading had higher specificity but similar sensitivity to 
England’s and the hybrid scheme (Figure 3). Assuming that automated grading 
was implemented for a similar cost to manual grading, it has the potential to 
produce a similar number of QALYs, but at a lower overall cost to the health 
service, than either England’s or the hybrid scheme.  Automated grading could 
be made cost-effective in Scotland, but an operating point at a higher specificity 
would have to be chosen.  
Deterministic sensitivity analysis suggested that monitoring patients with 
suspected diabetic macular oedema (on a 6-monthly basis) with OCT and retinal 
photography remained cost saving up to an incremental cost of ~£58 per 
patient. Further scenario analyses assessed the sensitivity of findings to 
alterations in assumptions and parameters in favour of the more sensitive and 
less specific strategies (see web appendix). Only when a number of parameters 
were simultaneously weighted in favour of the more sensitive strategies, did 
incremental cost per QALY approach the accepted threshold range (£20-30,000 
per QALY). 
TABLE 5 Sensitivity and specificity for the various manual grading schemes and for the operating point chosen for automated 
grading scheme. 
  Unweighted     Weighted   
N=3170 
Macular Oedema N=243 
N=3170 
Macular Oedema N=176 
Schem
e 
N 
referre
d 
N not 
referr
ed 
Sen
s % 
95%
CI 
95%
CI 
Spe
c % 
95%
CI 
95%
CI 
N 
referre
d 
N not 
referre
d 
Sen
s % 
95%
CI 
95%
CI 
Spe
c % 
95%
CI 
95%
CI 
Scottis
h  
1450 1720 82·
3 
77·0 86·6 57·
3 
55·5 59·1 734 2436 59·
5 
52·1 66·4 79·
0 
77·5 80·4 
Englis
h  
1441 1729 81·
5 
76·1 85·9 57·
5 
55·7 59·3 1122 2048 72·
6 
65·6 78·7 66·
8 
65·1 68·5 
Hybrid 1603 1567 88·
1 
83·4 91·6 52·
5 
50·7 54·3 1001 2169 73·
3 
66·3 79·3 70·
9 
69·2 72·5 
Auto-
mated 
1154 2015 82·
7 
77·5 87·0 67·
4 
65·7 69·1 921 2248 75·
9 
69·1 81·6 73·
7 
72·1 75·2 
 
TABLE 6 Expected costs, years free from moderate visual loss and quality adjusted life years per patient over a twenty year 
period using alternative screening strategies (based on a simulated cohort of 100,000 patients with macular pathology) 
Scheme 
Total 
cost 
(mean
) 
Increment
al cost 
Years 
free from 
moderate 
visual 
loss 
(mean) 
Incremental 
years free 
from 
moderate 
visual loss 
Incremental 
cost per 
year free of 
moderate 
visual loss 
quality 
adjusted 
life 
years 
(mean) 
Incremental 
quality 
adjusted 
life years 
Incremental 
cost per 
quality 
adjusted 
life year 
Ranking 
at Rc, 
£30,00
0  
Scottish  £2164 * 10·2631 * * 8·7029 * * 1 
English  £2374 £210 10·2703 0·0072 £29,170 d 8·7033 0·0004 £473,005 d 4 
Hybrid  £2320 £156 10·2700 0·0069 £22,583 d 8·7033 0·0004 £353,927 d 3 
Automate
da 
£2277 £113 10·2709 0·0078 £14,399 8·7034 0·0005 £222,210 2 
Scottish + 
OCT 
£1814 * 10·2631 * * 8·7029 * * 1 
English + 
OCT 
£1965 £151 10·2703 0·0072 £20,975 d 8·7033 0·0004 £340,113 d 4 
Hybrid + 
OCT 
£1925 £111 10·2700 0·0069 £16,069 d 8·7033 0·0004 £251,833 d 3 
Automate
d + OCT a 
£1894 £80 10·2709 0·0078 £10,194 8·7034 0·0005 £157,317 2 
Scheme A 
+ OCT 
£2109 £295 10·2788 0·0157 £18,832 8·7038 0·0009 £329,497 5 
OCT optical coherence tomography 
* Reference scheme; a figures in table based on assumption that fully automated grading can be implemented at zero net 
increase in grading costs; d scheme more costly and less effective than an alternative scheme (dominated); Rc, ceiling ratio 
of willingness to pay per QALY gained
Figure 4 summarises the probabilistic sensitivity analysis results, showing that 
Scotland’s scheme retains the highest probability of being cost-effective up to a 
ceiling “willingness to pay” ratio of ~£240,000 per QALY when used in 
conjunction with OCT.  
DISCUSSION  
Comparison was made between England’s and Scotland’s maculopathy grading 
schemes, along with a hybrid scheme and an automated scheme. In the 
weighted analysis Scotland achieved a sensitivity of 59·5% and specificity of 
79·0%. England had a higher sensitivity (72·6%) but a lower specificity 
(66·8%). Compared to England, the hybrid scheme increased sensitivity by 
0·7% and specificity by 4·1%. 
Statistical analyses were completed at the patient level. This gave higher 
sensitivity and lower specificity for each scheme than if using a single eye per 
patient. However, the order of the performances and costs are unaffected 
compared to single eye analyses. 
Based on weighted data the English and hybrid schemes result in higher 
numbers of true cases being identified, costing an additional £910 and £639 per 
extra case in the first cycle of the model. However, the repetitive nature of 
interval screening compromises the cost-effectiveness of schemes that have 
lower specificity. While the more sensitive schemes gave rise to small increases 
in years free from moderate visual loss (≥ 15 ETDRS letters), this translated into 
very small increases in QALYs as such visual losses are associated with a modest 
utility decrement and may only affect the worst seeing eye. Furthermore, 
patients missed in one round of screening have a chance of being detected at 
the next.  
While the cost-effectiveness model assumed all patients referred with macular 
oedema undergo laser treatment, results remained robust when only those 
patients with macular oedema and visual acuity ≥0·3 logMar were modelled to 
incur treatment costs. With several parameter values and assumptions weighted 
in favour of the more sensitive schemes, the additional costs of these schemes 
(per QALY gained) remained above thresholds for cost-effectiveness.[19] 
With weighted data, automated grading (working at any operating point on its 
receiver operating characteristic curve) improved performance over the manual 
schemes. Cost effectiveness will depend on the operating point chosen, the costs 
of implementation, balanced against cost savings resulting from reductions in 
manual grading time and unnecessary referrals.[9]  
In this study, a variety of OCT scanners were used. A variation in detection of 
diabetic macular oedema between centres was noted, partly due to differences 
in the sensitivity of the scanner and partly due to case-selection. Cases missed 
by less sensitive scanners may have biased the estimated sensitivities and 
specificities, but most likely in the same directions for all schemes. Hence they 
are unlikely to have affected the broader inferences. 
Economic modelling suggests that the use of OCT in conjunction with 
photography within screening programmes, for patients with surrogate markers 
of oedema, is likely to be cost-effective. The estimated marginal cost of 
conducting OCT within the screening programme (£32) is low in comparison with 
the cost of referral to ophthalmology (£143) and consequent monitoring in the 
outpatient setting. As the analysis included a survey of costs and pathways of 
implementation in the participating centres the results can be applied across 
England and Scotland. 
We assumed that patients without treatment would progress at the rate 
observed in the Early Treatment Diabetic Retinopathy Study.[14] To assess the 
benefits of improved detection and referral, the best available evidence was 
used.[4,14,15] Although Ranibizumab has now been approved,[21] its impact on 
the cost-effectiveness of screening for macular oedema is unknown.  
Considering the comparison of alternative photographic grading schemes in 
England and Scotland for triggering referral to ophthalmology or an OCT 
examination, we found Scotland’s scheme to be preferred based on weighted 
data when applying a ceiling ratio of £30,000 per QALY gained. 
Automated grading benefits from the ability to choose different operating points, 
depending on the sensitivity desired. At the study’s chosen operating point, if it 
could be implemented without increasing grading costs, automation could 
produce a similar number of QALYS for a lower overall cost than England’s 
scheme. Automated grading could be made cost-effective in Scotland, but an 
operating point at a higher specificity would have to be chosen. 
Utilising optical coherence tomography, as part of the screening pathway, could 
reduce costs to the health service.  
Retinal screening programmes in the United Kingdom should reconsider the 
screening pathway to make best use of existing and new technologies. 
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Figure legends: 
FIGURE 1 Study design for recruitment, with hybrid manual grading scheme as 
the diagnostic test and with the reference standard of macular oedema 
presence. “Positive” means that the image was judged to have macular oedema. 
 
FIGURE 2 Study design for recruitment, with automated image analysis as the 
diagnostic test and with the reference standard of macular oedema presence. 
“Positive” means that the image was judged to have macular oedema. 
 
FIGURE 3 Unweighted a) and weighted b) receiver operating characteristics 
curves for fully automated annotation grading including the operating point 
chosen. The performances of the manual schemes associated with current United 
Kingdom grading practice (England and Scotland), and of the manual grading 
schemes used in the economic analysis (hybrid manual) are also shown. 
 
FIGURE 4 Cost-effectiveness acceptability curves for the alternative grading 
schemes when used a) without OCT and b) with OCT prior to referral - based on 
a 20 year time horizon and using quality adjusted life years as the measure of 
outcome. 
 
